Rotavirus Infections - Pipeline Review, H1 2020
Rotavirus Infections - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.
Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical, Discovery and Unknown stages comprises 1, 3, 1, 1 and 1 molecules, respectively.
Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.
Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical, Discovery and Unknown stages comprises 1, 3, 1, 1 and 1 molecules, respectively.
Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rotavirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Rotavirus Infections - Overview
Rotavirus Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rotavirus Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rotavirus Infections - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals Inc
Beijing Minhai Biotechnology Co Ltd
Bharat Biotech Ltd
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Hilleman Laboratories Pvt Ltd
Medicago Inc
Micron Biomedical Inc
Pfizer Inc
Serum Institute of India Ltd
UMN Pharma Inc
Yisheng Biopharma Co Ltd
Rotavirus Infections - Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(rotavirus (virus like particle) + typhiod) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDG-5625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
poliomyelitis vaccine + rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rotavac-5C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes A1, A2, A3, A4] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes G1, G2, G3, G4, P1(8)] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RV-3BB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RV-625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UMN-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rotavirus Infections - Dormant Projects
Rotavirus Infections - Product Development Milestones
Featured News & Press Releases
Jun 03, 2019: Rotavirus vaccine (Rotarix): patient group direction (PGD) template
Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification
Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus
Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate
Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus
Apr 26, 2012: GSK’s Rotarix To Be Introduced In Ghana
Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan
May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix
Oct 15, 1999: Wyeth Lederle Vaccines Voluntarily Withdraws from the Market its Rotavirus Vaccine RotaShield
Aug 31, 1998: Wyeth-Ayerst Receives FDA Licensure for RotaShield; First Vaccine for Use in the Prevention of Rotavirus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Rotavirus Infections - Overview
Rotavirus Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rotavirus Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rotavirus Infections - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals Inc
Beijing Minhai Biotechnology Co Ltd
Bharat Biotech Ltd
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Hilleman Laboratories Pvt Ltd
Medicago Inc
Micron Biomedical Inc
Pfizer Inc
Serum Institute of India Ltd
UMN Pharma Inc
Yisheng Biopharma Co Ltd
Rotavirus Infections - Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(rotavirus (virus like particle) + typhiod) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDG-5625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
poliomyelitis vaccine + rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rotavac-5C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes A1, A2, A3, A4] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus [serotypes G1, G2, G3, G4, P1(8)] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RV-3BB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RV-625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UMN-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rotavirus Infections - Dormant Projects
Rotavirus Infections - Product Development Milestones
Featured News & Press Releases
Jun 03, 2019: Rotavirus vaccine (Rotarix): patient group direction (PGD) template
Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification
Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus
Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate
Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus
Apr 26, 2012: GSK’s Rotarix To Be Introduced In Ghana
Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan
May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix
Oct 15, 1999: Wyeth Lederle Vaccines Voluntarily Withdraws from the Market its Rotavirus Vaccine RotaShield
Aug 31, 1998: Wyeth-Ayerst Receives FDA Licensure for RotaShield; First Vaccine for Use in the Prevention of Rotavirus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Rotavirus Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Rotavirus Infections - Pipeline by Aridis Pharmaceuticals Inc, H1 2020
Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
Rotavirus Infections - Pipeline by Bharat Biotech Ltd, H1 2020
Rotavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Rotavirus Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
Rotavirus Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H1 2020
Rotavirus Infections - Pipeline by Medicago Inc, H1 2020
Rotavirus Infections - Pipeline by Micron Biomedical Inc, H1 2020
Rotavirus Infections - Pipeline by Pfizer Inc, H1 2020
Rotavirus Infections - Pipeline by Serum Institute of India Ltd, H1 2020
Rotavirus Infections - Pipeline by UMN Pharma Inc, H1 2020
Rotavirus Infections - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
Rotavirus Infections - Dormant Projects, H1 2020
Number of Products under Development for Rotavirus Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Rotavirus Infections - Pipeline by Aridis Pharmaceuticals Inc, H1 2020
Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
Rotavirus Infections - Pipeline by Bharat Biotech Ltd, H1 2020
Rotavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Rotavirus Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
Rotavirus Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H1 2020
Rotavirus Infections - Pipeline by Medicago Inc, H1 2020
Rotavirus Infections - Pipeline by Micron Biomedical Inc, H1 2020
Rotavirus Infections - Pipeline by Pfizer Inc, H1 2020
Rotavirus Infections - Pipeline by Serum Institute of India Ltd, H1 2020
Rotavirus Infections - Pipeline by UMN Pharma Inc, H1 2020
Rotavirus Infections - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
Rotavirus Infections - Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development for Rotavirus Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Aridis Pharmaceuticals Inc
Beijing Minhai Biotechnology Co Ltd
Bharat Biotech Ltd
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Hilleman Laboratories Pvt Ltd
Medicago Inc
Micron Biomedical Inc
Pfizer Inc
Serum Institute of India Ltd
UMN Pharma Inc
Yisheng Biopharma Co Ltd
Number of Products under Development for Rotavirus Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Aridis Pharmaceuticals Inc
Beijing Minhai Biotechnology Co Ltd
Bharat Biotech Ltd
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Hilleman Laboratories Pvt Ltd
Medicago Inc
Micron Biomedical Inc
Pfizer Inc
Serum Institute of India Ltd
UMN Pharma Inc
Yisheng Biopharma Co Ltd
